quinidine sulfate

General Material Information

Preferred name	quinidine sulfate
Trivial Name	Quinidine sulfate
Short Description	cinchonan-9-ol, 6'-methoxy-, (9S)-, sulfate (2:1) (salt)
Formula	C40 H50 N4 O8 S
CAS Number	50-54-4
Deleted CAS Number	11034-22-3
ECHA Number	200-046-3
FDA UNII	140CU2322K
MDL	MFCD00135926
Bio Activity Summary	External link
NMR Predictor	External link
Synonyms	auriquin chinidine sulfate cin-quin cinchonan-9-ol, 6'-methoxy-, (9S)-, sulfate (2:1) (salt) (S)-[(2R,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;sulfuric acid kinichron (9S)-6'- methoxycinchonan-9-ol sulfate (2:1) (salt) quinicardine quinidate quinidex quinidine monosulfate quinidine sulfate (salt) quinidine sulfate, (2:1) (salt) quinidine sulphate quinitex systodin Cinchonan-9-ol, 6′-methoxy-, (9S)-, sulfate (2:1) Quinidine, sulfate (2:1) (salt) Cinchonan-9-ol, 6′-methoxy-, (9S)-, sulfate (2:1) (salt) Quinora NSC 10004 (9S)-6′-Methoxycinchonan-9-ol sulfate (2:1)

US / EU / FDA / JECFA / FEMA / Scholar / Patents

Google Scholar	Start search
Google Books	Start search
Google Patents	Start search
Perfumer & Flavorists	Start search
EU Patents	Start search
PubMeb	Start search
NCBI	Start search

Literature & References

	(S)-[(2R,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;sulfuric acid
NIST Chemistry WebBook:	Search Inchi
Canada Domestic Sub. List:	50-54-4
Pubchem (cid):	5768
Pubchem (sid):	134971499

Publications by PubMed
Long-term follow-up of atrial function after cardioversion of atrial fibrillation in horses.
Long-term efficacy of low doses of quinidine on malignant arrhythmias in Brugada syndrome with an implantable cardioverter-defibrillator: a case series and literature review.
Characteristics of J wave-associated idiopathic ventricular fibrillation: role of drugs.
AVP-923, a combination of dextromethorphan hydrobromide and quinidine sulfate for the treatment of pseudobulbar affect and neuropathic pain.
Involuntary emotional expression disorder in Alzheimer's disease - psychopharmacotherapy aspects.
Resonance light scattering study on the interaction between quinidine sulfate and congo red and its analytical application.
Use of propafenone for conversion of chronic atrial fibrillation in horses.
Dextromethorphan/quinidine sulfate for pseudobulbar affect.
Therapeutic strategies in congenital myasthenic syndromes.
Biowaiver monographs for immediate release solid oral dosage forms: quinidine sulfate.
Electrometric measurement of plasma, erythrocyte, and whole blood cholinesterase activities in healthy human volunteers.
Transvenous electrical cardioversion of atrial fibrillation in six horses using custom made cardioversion catheters.
Evaluation of the state of active ingredients in pharmaceutical preparations using fourier transform-Raman difference spectra.
Gateways to clinical trials.
Preparation of surfactant-free nanoparticles of methacrylic acid copolymers used for film coating.
Gateways to clinical trials.
Gateways to clinical trials.
Monitoring of drugs with a narrow therapeutic range in ambulatory care.
Effects of low-dose quinidine on ventricular tachyarrhythmias in patients with Brugada syndrome: low-dose quinidine therapy as an adjunctive treatment.
Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials.
Treatment of an ocular squamous cell carcinoma in a stallion with atrial fibrillation.
Validation of an electrometric blood cholinesterase measurement in goats.
Gateways to clinical trials.
New drug salt formation in biodegradable microspheres.
Variable electrocardiographic effects of short-term quinidine sulfate administration in Brugada syndrome.
Gateways to clinical trials.
Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.
Characterization of quinidine 3-hydroxylation as a probe for the CYP 3A enzyme using a novel capillary electrophoresis technique.
Rifampin and rifabutin drug interactions: an update.
Determination of (3S)-3-hydroxy quinidine for metabolism screening experiments using direct injection capillary electrophoresis and laser-induced fluorescence detection.
A direct injection capillary electrophoretic technique for miniaturized high-throughput metabolic screening of the CYP 3A4 enzyme using quinidine as a probe.
Metabolism of sulfinpyrazone sulfide and sulfinpyrazone by human liver microsomes and cDNA-expressed cytochrome P450s.
A high-performance liquid chromatographic assay for the determination of desbutylhalofantrine enantiomers in rat plasma.
Salt and cosolvent effects on ionic drug loading into microspheres using an O/W method.
Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6.
[Regulation of atrial fibrillation in horses with oral quinidine sulfate. Discussion of the disease picture in a typical case].
Temporal organization of atrial activity and irregular ventricular rhythm during spontaneous atrial fibrillation: an in vivo study in the horse.
Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.
Pharmacokinetic/pharmacodynamic analysis of tacrolimus-induced QT prolongation in guinea pigs.
Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.
Behavioral modulation induced by food odor aversive conditioning and its influence on the olfactory responses of an oscillatory brain network in the slug Limax marginatus.
Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. SOCESP Investigators. The Cardiology Society of São Paulo.
The quantitative determination of cilostazol and its four metabolites in human liver microsomal incubation mixtures by high-performance liquid chromatography.
Experimental treatment of the acute cardiovascular toxicity of caffeine.
Stability of bethanechol chloride, pyrazinamide, quinidine sulfate, rifampin, and tetracycline hydrochloride in extemporaneously compounded oral liquids.
Safety and efficacy of quinidine sulfate in slow-channel congenital myasthenic syndrome.
AChR channel blockade by quinidine sulfate reduces channel open duration in the slow-channel congenital myasthenic syndrome.
Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome.
Congenital myasthenic syndromes: clinical and genetic analysis of 18 patients.
New 5-aminoacyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-ones with antiarrhythmic activity.
Itraconazole increases plasma concentrations of quinidine.
Normalization of acquired QT prolongation in humans by intravenous potassium.
Regional attitudes of generalists, specialists, and subspecialists about management of atrial fibrillation.
Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.
Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis.
Characterization of the genetic polymorphism of dihydrocodeine O-demethylation in man via analysis of urinary dihydrocodeine and dihydromorphine by micellar electrokinetic capillary chromatography.
Loss of quinidine gluconate injection in a polyvinyl chloride infusion system.
Metoprolol metabolism via cytochrome P4502D6 in ethnic populations.
The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation. Amiodarone vs quinidine for conversion of atrial fibrillation.
Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine Trial).
Exploration of the metabolism of dihydrocodeine via determination of its metabolites in human urine using micellar electrokinetic capillary chromatography.
A patient-side technique for real-time measurement of acetylcholinesterase activity during monitoring of eptastigmine treatment.
Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation. A decision analysis.
Treatment of atrial fibrillation in horses: new perspectives.
Quinidine-induced reversible pneumonitis.
[Echocardiography and therapy of atrial fibrillation in horses].
Different mechanisms of the inhibition of the transient outward current in rat ventricular myocytes.
Quinidine-enhanced beta-blockade during treatment with propafenone in extensive metabolizer human subjects.
Evaluation of the pharmacokinetic and pharmacodynamic interaction between quinidine and nifedipine.
Sotalol and type IA drugs in combination prevent recurrence of sustained ventricular tachycardia.
Structure of 9-epiquinine hydrochloride dihydrate versus antimalarial activity.
[A case of repetitive monomorphic ventricular tachycardia].
Stereochemical evaluation of the relative activities of the cinchona alkaloids against Plasmodium falciparum.
Photosensitivity induced by quinidine sulfate: experimental reproduction of skin lesions.
Behavioral analysis of internal memory states using cooling-induced retrograde amnesia in Limax flavus.
Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans.
Drug-induced esophagitis.
Altered absorption of digoxin, sustained-release quinidine, and warfarin with sucralfate administration.
The efficacy of isoproterenol on quinidine induced torsade de pointes.
A randomized controlled trial of quinidine in the treatment of cirrhotic patients with muscle cramps.
[Efficacy of isoproterenol, magnesium sulfate and verapamil for torsade de pointes].
Long-term community hospital experience with the internal defibrillator.
Drug administration in relation to meals in the institutional setting.
Anticholinergic effect of quinidine sulfate on guinea pig smooth muscle.
Pharmacokinetics and bioavailability of quinidine sulfate following direct injection to the abomasum in healthy cows.
Effect of magnesium sulfate on ventricular refractoriness and its efficacy for torsade de pointes.
Pharmacokinetics of propafenone enantiomers in rats.
Septicemia, atrial fibrillation, cardiomegaly, left atrial mass, and Rhodococcus equi septic osteoarthritis in a foal.
The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine.
Comparison of the effects of intravenous LNC-834, a new antiarrhythmic agent, and quinidine in canine models of arrhythmia.
Comparative bioavailability characteristics of commercial quinidine polygalacturonate and sulfate tablets.
Anticholinergic action of quinidine sulfate in the rabbit atrioventricular node.
Influence of dissolution rate and pH of oral medications on drug-induced esophageal injury.
Quinidine does not alter antipyrine metabolism.
Evaluation of biodegradable poly(lactide) pellets prepared by direct compression.
Pharmacokinetics of quinidine sulfate in dairy cattle.
Long-standing hiccup in a patient with sarcoidosis.
Extracellular Ca2+ controls outward rectification by apical cation channels in toad urinary bladder: patch-clamp and whole-bladder studies.
Quinidine: an update on therapeutics, pharmacokinetics and serum concentration monitoring.
Application of 1H-nuclear magnetic resonance spectroscopic method for quinidine to simultaneous determination of quinidine and dihydroquinidine in quinidine sulfate tablets.
Properties of verapamil-hypersensitive multidrug-resistant Chinese hamster ovary cells.
Lack of effect of cimetidine on the metabolism of quinidine: effect on renal clearance.
Crystal and molecular structure of the antimalarial agent 4-(tert-butyl)-2-(tert-butylaminomethyl)-6-(4-chlorophenyl)phenol dihydrogen phosphate (WR 194,965 phosphate).
Effect of diphenoxylate with atropine sulfate on the bioavailability of quinidine sulfate in healthy subjects.
Membrane actions of quinidine sulfate in the rabbit atrioventricular node studied by voltage clamp method.
Single-dose comparative kinetics and bioavailability study of quinine hydrochloride, quinidine sulfate and quinidine bisulfate sustained-release in healthy male volunteers.
Factors affecting prognosis and conversion in equine atrial fibrillation.
Fluoride-induced hyperkalemia: the role of Ca2+-dependent K+ channels.
The preparation and evaluation of drug-containing poly(dl-lactide) microspheres formed by the solvent evaporation method.
Comparative efficacy and safety of oral mexiletine and quinidine in benign or potentially lethal ventricular arrhythmias.
Indecainide compared with quinidine for chronic stable ventricular arrhythmias secondary to coronary artery disease or to cardiomyopathy.
Effects of quinidine sulfate on the balance among active and passive cellular properties that comprise the electrophysiologic matrix and determine excitability in sheep Purkinje fibers.
Atrial fibrillation in a pregnant mare: treatment with quinidine sulfate.
Quinidine effect on hydrosmotic response of collecting tubules to vasopressin and cAMP.
Cytosolic calcium and the action of vasopressin in toad urinary bladder.
Comparison of high pressure liquid chromatography and fluorescence polarization immunoassay to assess quinidine pharmacokinetics.
Skeletal muscle weakness resulting from quinidine ingestion.
Comparative quinidine plasma profiles at steady state of two controlled-release products and quinidine sulfate in solution.
Relationship between planar and all-surface rate constants for drugs formulated in nondisintegrating cylindrical slow-release tablets.
Comparison of sustained-release quinidines given twice daily to patients with ventricular ectopy.
[The electrophysiologic effect and anticholinergic action of quinidine sulfate on the atrioventricular node in the rabbit].
Adverse reactions to antiarrhythmic drugs during therapy for ventricular arrhythmias.
Epicardial activation patterns of torsade de pointes in canine hearts with quinidine-induced long QT interval but without myocardial infarction.
Quinidine-induced hepatitis. A common and reversible hypersensitivity reaction.
Comparative study of encainide and quinidine in the treatment of ventricular arrhythmias.
A new model of ventricular fibrillation induced by isoprenaline and catechol-O-methyl transferase inhibitor at a high perfusion temperature in isolated rat hearts.
Comparative efficacy and safety of short-acting and sustained release quinidine in the treatment of patients with ventricular arrhythmias.
Drug-induced torsade de pointes.
Comparative efficacy and safety of oral tocainide and quinidine for benign and potentially lethal ventricular arrhythmias.
Intravenous quinidine: relations among concentration, tachyarrhythmia suppression and electrophysiologic actions with inducible sustained ventricular tachycardia.
Long-term antiarrhythmic therapy. Problem of low drug levels and patient noncompliance.
[Comparative study of a slow-release quinidine preparation and flecainide administered in 2 daily doses for the treatment of extrasystole].
Analysis of Cinchona alkaloids by high-performance liquid chromatography. Application to the analysis of quinidine gluconate and quinidine sulfate and their dosage forms.
Effects of diltiazem on plasma and tissue digoxin levels in mice.
Pharmacokinetics of quinidine and three of its metabolites in man.
Effect of ethanol and pH on the adsorption of drugs to activated charcoal: studies in vitro and in man.
Effect of caffeine on the oral absorption and disposition of quinidine.
Quinidine-induced agranulocytosis.
Effect of cimetidine on the pharmacokinetics and pharmacodynamics of quinidine.
A randomized, double-blind, parallel group comparison of disopyramide phosphate and quinidine in patients with cardiac arrhythmias.
Flecainide versus quinidine for treatment of chronic ventricular arrhythmias. A multicenter clinical trial.
Effect of food and an antacid on quinidine bioavailability.
1-[4-(2-ter-butyl-quinolyl)]-3-(4-piperidyl)propanol (PK 10139): a new potent and long-acting antiarrhythmic agent.
[The anti-arrhythmia drug quinidine as an alternative in the treatment of severe falciparum malaria].
Improved Ellman procedure for erythrocyte cholinesterase.
Steady-state bioavailability of two sustained-release quinidine preparations: quinidine gluconate versus quinidine sulfate.
Concurrent use of quinidine and disopyramide: evaluation of serum concentrations and electrocardiographic effects.
Atrial pacing from the esophagus in the diagnosis and management of tachycardia and palpitations.
Antiarrhythmic effect of disulfiram in various cardiotoxic models.
Interaction of antacids with antiarrhythmics. V. Effect of aluminium hydroxide and magnesium oxide on the bioavailability of quinidine, procainamide and propranolol in dogs.
[Relative bioavailability of various quinidine preparations in man after a single oral dose].
Bioavailability of a commercial sustained-release quinidine tablet compared to oral quinidine solution.
Atrial fibrillation in horses: factors associated with response to quinidine sulfate in 77 clinical cases.
Rapid elimination of quinidine in pediatric patients.
Short- and long-term therapeutic efficacy of quinidine sulfate for the treatment of chronic ventricular arrhythmias.
Use of control steady-state serum digoxin levels for predicting serum digoxin concentration after quinidine administration.
Variability of spontaneous and exercise-induced ventricular arrhythmias in the absence and presence of treatment with acebutolol or quinidine.
Multifocal or chaotic atrial rhythm: report of nine infants, delineation of clinical course and management, and review of the literature.
Assessment of oral quinidine effects on sinus node function in sick sinus syndrome patients.
Anomalous dispersion of sulfur in quinidine sulfate, (C(20)H(25)N(2)O(2))(2)SO(4).2H(2)O: Implications for structure analysis.
Effects of quinidine on atrioventricular nodal reentrant paroxysmal tachycardia.
Pharmacokinetic analysis of intravenously and orally administered quinidine in cows.
Digoxin retinal toxicity. Clinical and electrophysiological evaluation of a cone dysfunction syndrome.
Decreased quinidine plasma protein binding during hemodialysis.
Pharmacokinetic analysis of intravenously and orally administered quinidine in horses.
Automated discrete kinetic method for erythrocyte acetylcholinesterase and plasma cholinesterase.
Bioavailability of 11 quinidine formulations adn pharmacokinetic variation in humans.
One-trial associative learning modifies food odor preferences of a terrestrial mollusc.
Contact sensitivity to quinidine sulfate from occupational exposure.
Effect of tocainide and quinidine on premature ventricular contractions.
Alteration of digoxin pharmacokinetics by a single dose of quinidine.
[Paradoxic response to disopyramide and quinidine (author's transl)].
Gastrointestinal absorption of quinidine from some solutions and commercial tablets.
Mechanism and prevention of cardiac arrhythmias in chronic hemodialysis patients.
Quinidine-induced thrombocytopenia with pulmonary hemorrhage.
Clinical evaluation of antiarrhythmic effects of disopyramide by multiclinical controlled double-blind methods.
[Chemistry and biological properties of substituted 3-amino-1H-isoindoles (author's transl)].
Digoxin -- quinidine interaction.
Quinidine therapy in hospitalized patients with ventricular arrhythmias.
Myocardial contractility in patients with ischemic heart disease during long-term administration of quinidine and procainamide. Direct measurement of segmental shortening with radiopaque epicardial markers.
The use of quinidine sulfate throughout pregnancy.
Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies.
Relative bioavailability of quinidine gluconate and quinidine sulfate in healthy volunteers.
Control of refractory cardiac arrhythmias with amiodarone.
Blood collection techniques, heparin and quinidine protein binding.
Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol.
The noninterference of aluminum hydroxide gel with quinidine sulfate absorption: an approach to control quinidine-induced diarrhea.
Ventricular tachyarrhythmia due to cardiac sarcoidosis in a child.
Single and multiple dose pharmacokinetics of oral quinidine sulfate and gluconate.
Correlation of quinidine absorption with disintegration and dissolution rates.
Comparative clinical evaluation of two salts of quinidine using 24-hour Holter monitor recordings.
Elimination of the delta wave in the Wolff-Parkinson-White syndrome. A misleading indicator of therapeutic effectiveness.
Adverse reactions to quinidine in hospitalized patients: findings based on data from the Boston Collaborative Drug Surveillance Program.
Quinidine-induced agranulocytosis.
Comparative bioavaiability of four commercial quinidine sulfate tablets.
[Fever and transient leukopenia due to hypersensitivity to quinidine sulfate].
Multifocal atrial tachycardia.
Cardiac arrhythmias on swallowing.
The effect of quinidine sulfate on QRS duration and QT and systolic time intervals in man.
Effects of procainamide and quinidine sulfate in the Wolff-Parkinson-White syndrome.
Supraventricular tachycardia that mimics ventricular tachycardia.
[Heart and circulatory effects of quinidine stereoisomers].
Quinidine sulfate.
Disposition kinetics of two oral forms of quinidine.
[Disopyramide phosphate: electrophysiological and inotropic effects in isolated cat papillary muscles and comparison with quinidine (author's transl)].
Quinidine photosensitivity.
Coronary artery surgery for recurrent ventricular arrhythmias in patients with variant angina.
Dissolution rate of commercial dosage form of quinidine sulfate.
Effects of antiarrhythmic drugs on cardiac membrane conductances; a study using the Hodgkin and Huxley mathematical model.
Comparative binding of disopyramide phosphate and quinidine sulfate to human plasma proteins.
Letter: Reaction to quinidine sulfate.
[Intravenous infusion of quinidine sulfate for therapy of equine auricular fibrillation. Preliminary report].
Proceedings: The potentiation of the antiarrhythmic effects of quinidine sulfate, lidocaine and ajmaline by tween 80.
[Comparative study of absorption and distribution of quinidine arabogalactane sulfate and quinidine sulfate].
Electrocardiography for diagnosis and control of efficacy of oral quinidine sulfate in a case of atrial fibrillation in a Holstein cow.
[Case of acute quinidine sulfate poisoning].
[Therapeutic study of quinidine sulfate arabogalactan (longacor)].
[Case of ventricular tachycardia with specific reaction to quinidine sulfate and with remarkable therapeutic effect with propranolol (a beta-sympathetic receptor blockader)].
[Electrocardiographic findings in the course of acute quinidine sulfate poisoning].
[Persistance of biochemical characteristics in the denervated rat gastrocnemius muscle after abolition of muscular fibrillation by quinidine sulfate].
Conversion of atrial fibrillation with quinidine sulfate in a dog.
Quinidine-sulfate-induced hypoplastic anemia and agranulocytosis.
An effect of quinidine sulfate on the lipid-facilitated transport of calcium ions in cardiac muscle.
THE USE OF QUINIDINE SULFATE DURING MYOCARDIAL INFARCTION.
[BEHAVIOR OF SOME IMPORTANT BIOCHEMICAL CONSTANTS IN THE MYOCARDIAL TISSUE AFTER ACUTE INTOXICATION DUE TO QUINIDINE SULFATE AND INFLUENCE OF ADMINISTRATION OF CORI'S ESTERS].
EXTENDED ACTION QUINIDINE SULFATE.
THE RELATIONSHIP OF DOSAGE SCHEDULE TO THE BLOOD LEVEL OF QUINIDINE, USING ALL AVAILABLE QUINIDINE PREPARATIONS.
[ERRORS AND HAZARDS. RECURARIZATION AFTER QUINIDINE SULFATE].
[PROPOSALS FOR THE GERMAN PHARMACOPOEIAS. 16. QUINIDINE SULFATE].
[PROPOSALS FOR THE DEUTSCHE ARZNEIBUCH. 16. QUINIDINE SULFATE].
Preliminary experience with a long-acting quinidine sulfate preparation.
Maintenance quinidine therapy with a sustained-acting quinidine sulfate tablet.
[Ballistocardiographic changes produced in dogs by intravenous injection of quinidine sulfate].
[On the purity test for quinidine sulfate. 7. Communication on the behavior of alkaloid salt solutions in aluminum oxide columns].
Metabolic properties of quinidine; effects of quinidine sulfate on anaerobic carbohydrate metabolism of rat diaphragm.
The effect of gastric acidity on the absorption of quinidine sulfate from the gastrointestinal tract.
[Quinidine sulfate and strychnine nitrate valence determination with potassium thiocyanatomercurate].
Use of quinidine sulfate and of procaine amide in a patient with paroxysmal ventricular tachycardia.
Auricular fibrillation and cardiac failure; its treatment with quinidine sulfate.
Quinidine sulfate in propylene glycol by intramuscular injection in man.
Atypical secondary or symptomatic thrombocytopenic purpura developing with the use of quinidine sulfate.
Some effects of quinidine sulfate on the heart and circulation in man.
Intensity and duration of action of quinidine sulfate in auricular fibrillation and flutter as measured by the rate of the circus movement.
Correlation between the effect of quinidine sulfate on the heart and its concentration in the blood plasma.
Chronic auricular fibrillation; its treatment with quinidine sulfate.
Correlation between the effect of quinidine sulfate on the rate of the circus movement in auricular fibrillation and its concentration in the blood plasma.
Quinidine Sulfate.
The combined use of lantoside C and quinidine sulfate in the abolition of established auricular flutter.

Other Information

(IUPAC):	Atomic Weights of the Elements 2011 (pdf)
Videos:	The Periodic Table of Videos
tgsc:	Atomic Weights use for this web site
(IUPAC):	Periodic Table of the Elements
HMDB (The Human Metabolome Database):	Search
MedlinePlusSupp:	View
VCF-Online:	VCF Volatile Compounds in Food
ChemSpider:	View

Suppliers

ExtraSynthese

PhysChem Properties

Material listed in food chemical codex	No
Molecular weight	746.92510986328
Flash Point TCC Value	N/a
Solubility
water, 1.05E+04 mg/L @ 25 °C (exp)	Yes
water, 1.05e+004 mg/L @ 25 °C (est)	Yes

Safety Information

Safety information


Hazards identification

Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
None found.
GHS Label elements, including precautionary statements

Pictogram

Hazard statement(s)
None found.
Precautionary statement(s)
None found.
Oral/Parenteral Toxicity:
intravenous-cat LD50 16 mg/kg Polish Journal of Pharmacology and Pharmacy. Vol. 32, Pg. 833, 1980. intravenous-dog LDLo 19 mg/kg BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: TREMOR BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD Drugs under Experimental and Clinical Research. Vol. 10, Pg. 197, 1984. oral-guinea pig LD50 362 mg/kg Farmaco, Edizione Pratica. Vol. 35, Pg. 49, 1980. intravenous-guinea pig LDLo 117 mg/kg Farmaco, Edizione Pratica. Vol. 35, Pg. 49, 1980. oral-human TDLo 9600 mg/kg/8W BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES BEHAVIORAL: TREMOR JAMA, Journal of the American Medical Association. Vol. 238, Pg. 884, 1977. oral-man TDLo 88 mg/kg/10D-I LIVER: "HEPATITIS (HEPATOCELLULAR NECROSIS), DIFFUSE" Gastroenterology. Vol. 70, Pg. 1136, 1976. oral-man TDLo 240 mg/kg/2W-I ENDOCRINE: TUMORS MUSCULOSKELETAL: JOINTS SENSE ORGANS AND SPECIAL SENSES: CONJUNCTIVE IRRITATION: EYE Journal of Toxicology, Clinical Toxicology. Vol. 20, Pg. 367, 1983. oral-man TDLo 386 mg/kg/30D- BLOOD: CHANGES IN CELL COUNT (UNSPECIFIED) American Journal of Medicine. Vol. 77, Pg. 345, 1984. intraperitoneal-mouse LD50 135 mg/kg Journal of Pharmacology and Experimental Therapeutics. Vol. 124, Pg. 53, 1958. intravenous-mouse LD50 54 mg/kg Archives Internationales de Pharmacodynamie et de Therapie. Vol. 105, Pg. 221, 1956. oral-mouse LD50 505 mg/kg Farmaco, Edizione Pratica. Vol. 35, Pg. 49, 1980. intravenous-rabbit LD50 30 mg/kg Polish Journal of Pharmacology and Pharmacy. Vol. 32, Pg. 833, 1980. intravenous-rat LD50 55 mg/kg Polish Journal of Pharmacology and Pharmacy. Vol. 44, Pg. 187, 1992. oral-rat LD50 456 mg/kg Arzneimittel-Forschung. Drug Research. Vol. 18, Pg. 1127, 1968. intraperitoneal-rat LDLo 140 mg/kg Toxicology and Applied Pharmacology. Vol. 1, Pg. 156, 1959.
Dermal Toxicity:
subcutaneous-rat LD50 610 mg/kg Arzneimittel-Forschung. Drug Research. Vol. 18, Pg. 1127, 1968.
Inhalation Toxicity:
Not determined

Safety in use information

Category:
natural substances and extractives
Recommendation for quinidine sulfate usage levels up to:
	not for fragrance use.

Recommendation for quinidine sulfate flavor usage levels up to:
	not for flavor use.

Safety references

EPI System: View

ClinicalTrials.gov:search

Daily Med:search

AIDS Citations:Search

Cancer Citations:Search

Toxicology Citations:Search

EPA Substance Registry Services (TSCA):50-54-4

EPA ACToR:Toxicology Data

EPA Substance Registry Services (SRS):Registry

Laboratory Chemical Safety Summary :5768

National Institute of Allergy and Infectious Diseases:Data

WGK Germany:1

(S)-[(2R,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;sulfuric acid

Chemidplus:0000050544